The Value Of Being Decisive On Strategic Needs – Through One Pharma CEO's Lens
Executive Summary
After a promising research program failed to deliver, London-listed Circassia changed from being an R&D-based allergy company to one focused on commercial respiratory therapies. Rapid decision-making averted a crisis and earned the company a US deal and equity partnership with AstraZeneca. As an exercise in Plan B readiness, it's surely up there with the best.
You may also be interested in...
Circassia Puts Aside R&D, Aims To Grow Commercial Platform
UK biotech Circassia puts Phase III cat allergy vaccine failure behind it and intends to move forward with building its commercial platform, and sales, in the respiratory sector.
Mite Trial Failure 'The Final Straw' As Circassia Ends Anti-Allergy Investing
Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.